Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| These results were driven by strong growth in USPI's same-store volumes and net revenue per case, strong patient acuity and overall revenue growth in the hospitals and very effective expense controls throughout the businesses, with the management of contract labor costs as a notable example |
| Look, we think we have a lot of advantages based upon our scale, our physician relationships, our ability to deliver synergies, and also just the consistent, demonstrated operating excellence over a long period of time |
| 2023 was an exceptional year for Tenet |
| But most importantly, we remain committed to the portfolio that we have and running it at a high quality with solid earnings from that standpoint that we can deliver |
| We are very pleased with the strong finish of our fiscal 2023, with fourth quarter adjusted EBITDA coming in well above the high end of our most recent guidance ranges for both the USPI and the Hospital segments |
| This was driven by continued volume strength as well as cost and utilization management |
| First of all, we had an outstanding year in the hospital segment |
| As you know, every quarter, we exceeded our expectations there |
| The volume strength was also very good during the year |
| One of the things that we're going to be disciplined about is we're going to do good deals, high-quality assets, attractive multiples, not overpaying and ultimately being able to deliver earnings growth in those facilities and organic growth in those facilities in a way that we got it |
| So we're not going to chase a number, but our pipeline at this point makes me feel good about the fact that if things come together the right way, we could reach that target by the end of 2025 |
| Now I'd like to highlight some key items for each of our segments, beginning with USPI, which again delivered strong operating results in the fourth quarter |
| Throughout the year, we saw ongoing strength and recovery in GI, urology and ENT procedures |
| And that's a really, really good lesson learned from 2023, about our ability to actually deliver case volumes at that high level of productivity |
| In 2023, we added 30 centers to the portfolio, furthering our goal of creating additional lower cost sites of care for patients and physicians while delivering superior value for our stakeholders |
| Acuity remains strong with fourth quarter 2023 revenue per adjusted admission up 6.5% over prior year |
| Look, I would say that first of all, the comp in the first quarter is really, really strong based upon the recovery we saw |
| So we feel very good about that going forward |
| This best-in-class contract labor cost management performance helped drive strong results in 2023 and we expect to continue to benefit from our operational discipline in the future |
| In summary, we are very pleased with the performance of our teams in 2023 and believe that we will carry the momentum into the New Year |
| Total joint surgeries grew significantly in the fourth quarter, even above what we were running during the course of the year |
| First, in our industry leading ambulatory surgery business, we anticipate adjusted EBITDA growth of approximately 9% at the midpoint of our guidance in 2024 based on our expectations of ongoing strength in demand coupled with great visibility into our pricing, 3% to 6% growth in same facility revenue, continuous improvement in our operating efficiency and additional sites of care joining the portfolio |
| And now we add to that what we think is a best-in-class revenue cycle capability that we’ve built inside of USPI, separate from Conifer, inside of USPI, that is starting to do work even for non USPI centers, which is an exciting development |
| I mean we anticipate continued strong growth in the ambulatory surgery segment |
| We are very confident in the long-term growth rates of this business |
| We have consistently acquired centers at attractive valuations and achieved post synergy multiples to below five times while improving our quality and delivering a 96.6% overall patient experience score under our management |
| So I feel pretty good about the fact that our business development and strategic teams are thinking steps ahead |
| Our cash flow performance has improved substantially over the past several years, and we continue to demonstrate the ability to generate this cash flow while also deleveraging our balance sheet, maintaining investments in our business and executing on key growth plans |
| We believe adding centers with strong margins and attractive post synergy multiples remains the most effective use of our cash for investments to enhance Tenet’s earnings and free cash flow |
| This projected growth is expected to be driven by 1% to 3% adjusted admissions growth and continued operating discipline |
| Statement |
|---|
| On a per adjusted admission basis, fourth quarter Hospital SWB was 160 basis points lower than fourth quarter 2022 |
| Let me summarize the primary drivers as follows: First, we recognized $16 million of grant income in 2023; and second, we recorded income of $34 million associated with cybersecurity insurance proceeds in 2023; third, there are $98 million of headwinds for 2024 arising from the termination of COVID-related government funding programs in 2023, new regulations related to workers' compensation and personal injury reimbursement in Florida, and changes to health care wages due to the recent minimum wage loss in California; fourth, the closing of our South Carolina hospital sale on January 31st creates a year-over-year EBITDA headwind of $140 million; and finally, our California hospital sale is assumed to create a year-over-year EBITDA headwind of $55 million |
| In addition, during our third quarter earnings call, we said that we would overcome various reimbursement headwinds to grow EBITDA in 2024, which this guidance reflects |
| We are mindful of what got us here in the last five years operating excellence, disciplined capital allocation with a focus on ROIC, an analytics-driven culture and a continuous improvement mindset |
| And then we're mindful of the fact that there are some things in the operating environment to think about |
| Obviously, the headlines around the last couple of divestitures grabbed some headlines |
| In terms of strong expense management, our consolidated SWB was 43% of net revenues in the fourth quarter which was substantially lower than the 46.2% we saw in fourth quarter of 2022, and our consolidated contract labor rate was 2.8% of SWB, a material reduction from 7.3% in the fourth quarter of 2022 |
| For 2024 we are assuming some moderation in the rate of growth here |
| If you think about 2023 where we saw a lot of recovery in GI and ENT cases, even a relative mix shift could impact the acuity in 2024 |
| But if the business outperforms raising our guidance just like we did in 2023, if in fact, it's warranted |
Please consider a small donation if you think this website provides you with relevant information